Sol-gel Technologies Ltd. · NASDAQ:SLGL
Sol-gel Technologies — Investor Presentation (September 2026)
22 slides from Sol-gel Technologies's investor presentation, September 2026
Slide 1: Corporate Overview
Corporate Overview September 2026
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of historical fact should be considered forward-looking statement
Slide 3: Management Team
Management Team EYAL BEN-OR MORI ARKIN MICHAEL GLEZIN Chief Financial Officer Chief Executive Officer, Chairman Chief Business Officer DR. OFRA LEVY-HACHAM DR. ITZIK YOSEF DR. OFER TOLEDANO VP, Clinical and Regulatory Affairs Chief Operating Officer VP, Research and Development 3
Slide 4: Pipeline Focus on Skin Diseases with No Approved Therapeutics
Pipeline Focus on Skin Diseases with No Approved Therapeutics Research Preclinical Phase I Phase II Phase III FDA approval Gorlin syndrome Top-line results are expected in Q4 2026 High-frequency BCC Start in H2 2027-H1 2028 Undisclosed Indications PoC Start in H2 2026 Acne vulgaris Multiple agreemen
Slide 5: SGT-610: Patidegib Gel, 2%
SGT-610: PATIDEGIB GEL, 2% Prevention of New BCC in Gorlin Syndrome and High-Frequency BCC Patients 5 5
Slide 6: No Approved Preventive Treatments for Gorlin Patients
No Approved Preventive Treatments for Gorlin Patients • Gorlin syndrome (GS), also known as nevoid basal cell carcinoma syndrome (NBCCS), is a rare autosomal dominant disorder characterized by multiple early-onset basal cell carcinomas (BCCs), odontogenic keratocysts, and skeletal abnormalities¹ • G
Slide 7: Gorlin Syndrome Is a Rare Disease with a Significant Effect on Quality of Life
Gorlin Syndrome Is a Rare Disease with a Significant Effect on Quality of Life “BCCs are the most burdensome manifestation reported by Gorlin syndrome patients. The volume of BCCs in Gorlin syndrome and associated need for repeated treatments leads to significant permanent scarring, anxiety, and los
Slide 8: Gorlin Syndrome Patients Require Frequent Removal of BCCs
Gorlin Syndrome Patients Require Frequent Removal of BCCs Patients repeatedly undergo painful surgeries until further excision becomes impractical BCC Removal Surgery Skin Transplantation 8
Slide 9: SGT-610 Topical Patidegib for the Prevention of New BCCs in Gorlin Syndrome
SGT-610 Topical Patidegib for the Prevention of New BCCs in Gorlin Syndrome • Sol-Gel is developing SGT-610 (topical patidegib 2%), New Chemical Entity, to prevent the formation of new BCCs in adults with Gorlin syndrome (GS); patidegib is designed to inhibit Smoothened (SMO), a key transmembrane pr
Slide 10: Well-Established Mechanism of Action for SGT-610
Well-Established Mechanism of Action for SGT-610 Normal PTCH1 Mutated PTCH1 Topical Patidegib in Use Patidegib Antagonizes SMO in the Hedgehog Pathway Hh = hedgehog; Ptch = patched receptor; Smo = smoothened receptor; GLI1 = glioma-associated oncogene 1; SUFU = suppressor of fused homolog gene 10
Slide 11: SGT-610: Topical Hedgehog Inhibitor for Long Term Prevention of New BCC
SGT-610: Topical Hedgehog Inhibitor for Long Term Prevention of New BCC in Gorlin Syndrome Oral Hedgehog Inhibitors Are Unsuitable for the Prevention Therapy Oral hedgehog inhibitors are approved for metastatic or locally advanced BCC; treatment is frequently limited by class-related adverse events1
Slide 12: Why We Believe the SGT-610 Phase 3 Study is Positioned to Succeed
Why We Believe the SGT-610 Phase 3 Study is Positioned to Succeed • Our study includes high-burden patients that are most likely to respond to patidegib during the study period • Our study does not include patients without PTCH1 mutation, which were identified by us as non-responders In a post-hoc a
Slide 13: PTCH1-Positive, High-Burden BCC Subgroup Demonstrated Statistically Significant Results
PTCH1-Positive, High-Burden BCC Subgroup Demonstrated Highly Beneficial, Statistically Significant Results Post-Hoc Analysis on Observed Data New BCCs Excluding non-Suspicious by Month New BCCs Excluding non-Suspicious by Month, ITT, Observed ITT, Observed1 >10 BCCs at baseline with PTCH1 mutation 8
Slide 14: PTCH1 Mutation Linked to Higher Efficacy
PTCH1 Mutation Linked to Higher Efficacy Post-Hoc Analysis in High-Burden Patients with or without PTCH1 Mutation, ITT Observed Number of new BCCs Excluding non-Suspicious, Observed, >10 BCCs at Baseline with or without PTCH1 mutation 10 Patidegib no mutation in PTCH1 Patidegib with mutation in PTCH
Slide 15: Key Learnings from PellePharm to Design Phase 3 With Enhanced Probability of Success
Key Learnings from PellePharm to Design Phase 3 With Enhanced Probability of Success Key Inclusion Criteria Study Execution Improvements • BCC verification for each lesion by dermoscopic analysis is mandatory # of BCC on the face ≥3 ≥10 • Central Photography Review Board led by KOLs have been Patien
Slide 16: Phase 3 Clinical Trial Design (Topline Results Expected in Q4 2026)
Phase 3 Clinical Trial Design (Topline Results Expected in Q4 2026) Sites & Subjects 41 active sites in the US, EU and UK SGT-610 (patidegib) gel, 2%, BID All patients has been recruited Endpoints Primary: Number of new BCCs Screening 1:1 M-0 M-3 M-6 M-9 M-12 Key Secondary: Number of new SEBs Tighte
Slide 17: No Safety Signal Identified in Previous Phase 3 Clinical Trial
No Safety Signal Identified in Previous Phase 3 Clinical Trial Patidegib gel demonstrated safety and tolerability profiles similar to vehicle Related SAEs None Related TEAEs Patidegib – 26 subjects; Vehicle – 28 subjects Related TEAEs leading to discontinuation: Patidegib – 3 subjects (diarrhea, Dis
Slide 18: SGT-610: >$600M Peak Sales Opportunity in Gorlin Syndrome
SGT-610: >$600M Peak Sales Opportunity in Gorlin Syndrome Treatable population External validation: Expected annual net price ~$270K $760M + Double Digit royalties2 Prevalence • Based on assessment performed for Sol-Gel by 11,000 GS patients in the US1 • Minimal rebating for expected broad use / min
Slide 19: High-frequency BCC: A Broader Opportunity in Addition to Gorlin Syndrome
High-frequency BCC: A Broader Opportunity in Addition to Gorlin Syndrome • Somatic PTCH1 mutations can drive BCC formation, which may progress to multiple BCCs under environmental and epigenetic influences • High-frequency basal cell carcinoma (HF-BCC) is defined as more than 9 BCC/3 years1 • Accord
Slide 20: Summary
• Gorlin syndrome patients live with BCCs every day; Any improvement is significant • Oral hedgehog inhibitors treat BCCs, but significant adverse reactions limit the ability of patients to use them for prevention • Patidegib is a topical hedgehog inhibitor; No safety signal identified in previous c
Slide 21: SGT-210: Topical Erlotinib
SGT-210: TOPICAL ERLOTINIB First Topical EGFRi, PoC studies H2 2026 21
Slide 22: SGT-210: Topical Erlotinib Platform Advancing Toward New Feasibility Studies
SGT-210: Topical Erlotinib Platform Advancing Toward New Feasibility Studies • Topical erlotinib platform designed for local EGFR inhibition with limited systemic exposure • Compassionate-use treatment in a pediatric patient with Olmsted syndrome, an ultra-rare debilitating skin disorder with no app
Sol-Gel Technologies — Investor Presentation (September 2026) on 6ix